zongertinib

News

Boehringer advances duo for aggressive cancers into phase 3

Boehringer Ingelheim steps up its push into oncology with phase 3 trials for pathfinder product Hernexeos and obrixtamig in hard-to-treat cancers.

News

Boehringer back in cancer with Hernexeos approval

Boehringer Ingelheim's bid to return to the oncology arena has been achieved with an FDA approval for lung cancer therapy Hernexeos.

News

Bayer files HER2+ lung cancer drug in China

Bayer files its oral HER2+ lung cancer drug in China, as it extends a race to market with rival Boehringer Ingelheim.

News

Boehringer eyes H2 drug launches after strong H1 growth

Boehringer Ingelheim is preparing for multiple drug launches in the second half of 2025,

News

Boehringer eyes third quarter FDA verdict for oral HER2 drug

Boehringer Ingelheim's oral HER2 inhibitor zongertinib has started an FDA review as a lung cancer treatment with a decision due in the third quarter.

News

WCLC: Bayer, Boehringer face off on HER2 cancers

Bayer and Boehringer Ingelheim both had new data on their HER2-targeting small-molecule drugs to present at the World Conference on Lung Cancer (WCLC), hoping to add new oral therapies to t

Boehringer advances duo for aggressive cancers into phase 3

Boehringer back in cancer with Hernexeos approval

Bayer files HER2+ lung cancer drug in China

Boehringer eyes H2 drug launches after strong H1 growth

Boehringer eyes third quarter FDA verdict for oral HER2 drug

WCLC: Bayer, Boehringer face off on HER2 cancers

EMA advisors say CSL's Tavneos should be pulled from sale

Discover a new era of healthcare panel engagement: Grounded ...

zongertinib

Editor's Picks